Should You Buy This Big Pharma Stock?
Two characteristics are indicative of a pharma stock that can meaningfully increase a shareholder's wealth over the long term. First, a prospective stock should have a diversified portfolio of cutting-edge therapies on the market. Second, the stock should have a good amount of potential blockbuster drugs in its pipeline and undergoing clinical trials. These two traits allow for a stock's revenue and earnings capacity to keep growing consistently.
AstraZeneca (NASDAQ: AZN) is one pharma stock that appears to meet these requirements. But is it a buy? Let's dive into the stock's fundamentals and valuation to try to answer that question.
Source Fool.com